Public‐private partnerships as driving forces in the quest for innovative medicines-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Public‐private partnerships as driving forces in the quest for innovative medicines

Published:2013-01-15 Issue:1 Volume:2 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical and Translational Medicine

Author:

Goldman Michel¹,Compton Carolyn²,Mittleman Barbara B³

Affiliation:

1. Innovative Medicines InitiativeTO 56, Office 6/4, 1049BrusselsBelgium

2. Critical Path Institute1730 East River Road85718TucsonAZUSA

3. National Institutes of Health Program on Public‐Private Partnerships9000 Rockville Pike20892BethesdaMarylandUSA

Publisher

Wiley

Subject

Molecular Medicine,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1186/2001-1326-2-2

Reference8 articles.

1. The FDA Critical Path Initiative and Its Influence on New Drug Development

2. European Technology Platform on Innovative Medicines

3. The innovative medicines initiative;Goldman M;A European response to the innovation challenge. Clin Pharmacol Ther,2010

4. Precompetitive Research: A New Prescription for Drug Development?

5. Urinary clusterin, cystatin C, β2-microglobulin and total protein as markers to detect drug-induced kidney injury

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Project-Based Public–Private Collaborations;Handbook of Experimental Pharmacology;2024

2. Optimal pediatric drug development— the partnership between patients/parents, academia, regulatory authorities and industry;Essentials of Translational Pediatric Drug Development;2024

3. Study on the evolutionary game of the three parties in the combined medical and health-care PPP project;Frontiers in Public Health;2023-01-26

4. The costs of developing treatments for Alzheimer's disease: A retrospective exploration;Alzheimer's & Dementia;2021-09-28

5. Who funds Alzheimer's disease drug development?;Alzheimer's & Dementia: Translational Research & Clinical Interventions;2021-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3